Safety, Pharmacokinetics, and Pharmacodynamics of Etavopivat (FT-4202), an Allosteric Activator of Pyruvate Kinase-R, in Healthy Adults: A Randomized, Placebo-Controlled, Double-Blind, First-in-Human Phase 1 Trial.
Sign Up to like & getrecommendations! Published in 2022 at "Clinical pharmacology in drug development"
DOI: 10.1002/cpdd.1058
Abstract: Etavopivat (FT-4202) is an orally administered, small-molecule allosteric activator of erythrocyte pyruvate kinase-R (PKR) in clinical development for the treatment of sickle cell disease and other hemoglobin disorders. This randomized, placebo-controlled, double-blind, first-in-human combination single-ascending… read more here.
Keywords: safety; placebo; randomized placebo; allosteric activator ... See more keywords